---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-032780"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:28:45.839491+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs and Ono Pharma collaborate on fusion proteins; upfront $9M, milestones up to $217.5M

## Summary
- Upfront payment plus research milestones total up to $9M; Ono reimburses all research costs.
- Exclusive option for Ono to license compounds after research; exercise triggers up to $217.5M in development, regulatory, and commercial milestones.
- Tiered royalties on global net sales: mid-single digit to low double digit percentages per product/country for 10 years.
- Parties cannot commercialize products with same mechanism of action globally during the agreement term.
- Ono can terminate on 90 days' notice; Shattuck can terminate if Ono abandons development after option exercise.

## SEC filing metadata
- accession: 0001193125-24-032780
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000119312524032780/0001193125-24-032780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000119312524032780/d780650d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-032780
- JSON: https://secwatch.observer/filing/0001193125-24-032780.json
- Plain text: https://secwatch.observer/filing/0001193125-24-032780.txt

## Key facts
- Material Agreements
  Shattuck Labs, Inc. entered into Collaboration Agreement with Ono Pharmaceutical Co., Ltd valued at Up to $9 million in upfront and milestone payments for research plan, plus potential milestone payme (effective 2024-02-13).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Ono Pharmaceutical Co., Ltd
  - Value: Up to $9 million in upfront and milestone payments for research plan, plus potential milestone payme
  - Effective: 2024-02-13
  source text: On February 9, 2024, Shattuck Labs, Inc. (“Shattuck”) entered into a collaboration and license agreement (the “Collaboration Agreement”) with Ono Pharmaceutical Co., Ltd (“Ono”), effective February 13, 2024, pursuant to which Shattuck and Ono will collaborate in the research and preclinical development of certain prespecified compounds directed toward a pair of targets selected by Ono from Shattuck’s pipeline of bifunctional fusion proteins (the “Development Compounds”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680367/000119312524032780/0001193125-24-032780-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.